Thailand Advances Medical-Only Cannabis Bill, Ending Adult Use

Medical Framework Replaces Open-Access Model

The bill establishes a prescription-only system that would shut down the estimated 6,000+ cannabis shops operating across Thailand. Only patients with documented medical conditions and physician authorization could legally access cannabis products. Recreational dispensaries, cannabis cafes, and tourist-facing retailers would be required to close or transition to licensed medical facilities. Most operators say that conversion isn't financially possible.

There's no grandfathering provision for existing businesses. Shop owners who invested in storefronts, inventory, and licenses under the 2022 decriminalization framework face complete loss unless they can secure medical dispensary licenses—which require hospital affiliation or pharmacy credentials under the draft text.

Parliamentary Timeline and Enforcement Date

The bill passed its second reading in Thailand's National Assembly with 198 votes in favor and 136 opposed. Final vote: October 15, 2026. If enacted, the law takes effect 90 days after royal assent, placing the enforcement deadline in mid-January 2027.

That three-month window is the only transition period built into the legislation. No compensation mechanism exists for displaced workers or business owners. Industry groups estimate the ban would eliminate 15,000 to 20,000 jobs in retail, cultivation, and processing, most of them created since decriminalization.

What Triggered the Reversal

Thailand's conservative coalition government, elected in May 2025, campaigned explicitly on reversing decriminalization. Prime Minister Srettha Thavisin's administration cited public health concerns, youth access, and tourism image as justifications. The government released no data quantifying underage use or health harms tied to the adult-use market.

The shift reflects a political calculation more than an evidence-based policy change—no ministry has published adverse event data or youth consumption surveys that would justify the abrupt closure of a legal industry.

Decriminalization in 2022 occurred under a different government. That policy removed cannabis from the narcotics list but didn't establish a regulated adult-use framework, leaving enforcement ambiguous and allowing a gray-market boom.

Medical Licensing Requirements and Access Barriers

The bill defines eligible medical conditions narrowly: chronic pain, chemotherapy side effects, epilepsy, and multiple sclerosis. Patients must obtain a prescription from a licensed physician and register with the Ministry of Public Health. Cannabis products would be dispensed only through hospital pharmacies or standalone medical dispensaries that meet facility and staffing requirements similar to those for controlled pharmaceuticals.

For context on how Thailand's shifting cannabis policy fits into the broader regional picture, see the CannIntel topic hub on Thailand Cannabis Policy.

The system mirrors pre-2022 medical programs that served fewer than 5,000 patients nationwide. Critics say the prescription requirement and hospital-based distribution model would effectively eliminate access for the estimated 1.2 million Thais who currently purchase cannabis products from retail shops.

Industry Response and Legal Challenges

Cannabis business owners filed a constitutional challenge on September 20, arguing the law violates property rights and economic freedoms guaranteed under Thailand's 2017 constitution. The case is pending before the Constitutional Court. No timeline for review yet. Legal experts say the court rarely grants injunctions to block legislation before it takes effect.

The Thai Cannabis Trade Association announced it would seek an emergency injunction if the bill passes its final reading. It represents approximately 3,000 licensed retailers and cultivators. No major political party has pledged to block the legislation or propose amendments that would preserve adult-use access.

Enforcement Uncertainty and Cross-Border Implications

The bill doesn't specify penalties for possession or sale after the enforcement date, leaving that to subsequent ministerial regulations. Draft enforcement guidelines circulated in August proposed penalties ranging from fines of 20,000 to 100,000 baht ($550 to $2,750 USD) for possession to prison terms of up to five years for unlicensed sales. Those guidelines haven't been finalized.

Thailand's reversal puts it at odds with Laos, which is moving toward regulated adult use, and Malaysia, where medical cannabis remains restricted but decriminalization is under legislative review. No other Southeast Asian country has attempted and then reversed cannabis decriminalization on this timeline.

Watch the Constitutional Court's response to the injunction request, expected within 30 days of the final vote. If the court declines to intervene, expect mass shop closures in December as operators liquidate inventory ahead of the January deadline.